Literature DB >> 877110

Strategy in the management of melanoma.

G Westbury.   

Abstract

Entities:  

Mesh：

Year:  1977        PMID： 877110      PMCID： PMC1543184     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN： 0035-9157


× No keyword cloud information.
  8 in total

1.  Salvage procedures for locally advanced malignant melanoma of the lower limb (with special reference to the role of isolated limb perfusion and radical lymphadenectomy).

Authors:  P C Weaver; J Wright; W L Brander; G Westbury
Journal:  Clin Oncol       Date:  1975-03

2.  Use of vaccinia virus in the treatment of metastatic malignant melanoma.

Authors:  I Hunter-Craig; K A Newton; G Westbury; B W Lacey
Journal:  Br Med J       Date:  1970-05-30

3.  Radical dissection of the inguinal and iliac lymph-nodes for malignant melanoma of the leg.

Authors:  G W Milton; A E Williams; D H Bryant
Journal:  Br J Surg       Date:  1968-09       Impact factor: 6.939

4.  Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience.

Authors:  E T Krementz; R F Ryan
Journal:  Ann Surg       Date:  1972-06       Impact factor: 12.969

5.  Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1975-11       Impact factor: 12.969

6.  Treatment of primary melanoma by intralesional vaccinia before excision.

Authors:  J D Everall; C J O'Doherty; J Wand; P M Dowd
Journal:  Lancet       Date:  1975-09-27       Impact factor: 79.321

Review 7.  The developmental biology of primary human malignant melanomas.

Authors:  W H Clark; A M Ainsworth; E A Bernardino; C H Yang; C M Mihm; R J Reed
Journal:  Semin Oncol       Date:  1975-06       Impact factor: 4.929

8.  Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.

Authors:  E S Newlands; C J Oon; J T Roberts; P Elliott; R F Mould; C Topham; F J Madden; K A Newton; G Westbury
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.